Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
KEYNOTE-522 study shows Keytruda plus chemotherapy improves overall survival in high-risk early-stage TNBC, with 5-year OS at 86.6% vs. 81.7% with placebo. Keytruda's OS benefits support its role as perioperative therapy, despite higher immune-related AEs. Keytruda outperforms Roche's Tecentriq in TNBC treatment, though T-cell exhaustion and resistance remain challenges.
Reference News
Merck & Co's Keytruda regimen in early-stage TNBC reduced death risk by 34% in KEYNOTE-522 trial, with 5-year OS rates of 86.6% vs 81.7%.
Keytruda plus chemotherapy significantly improved overall survival in high-risk early-stage TNBC, reducing death risk by 34% compared to chemotherapy alone, according to the Phase III KEYNOTE-522 trial.
KEYNOTE-522 study shows Keytruda plus chemotherapy improves overall survival in high-risk early-stage TNBC, with 5-year OS at 86.6% vs. 81.7% with placebo. Keytruda's OS benefits support its role as perioperative therapy, despite higher immune-related AEs. Keytruda outperforms Roche's Tecentriq in TNBC treatment, though T-cell exhaustion and resistance remain challenges.